A BILL 
To implement certain recommendations to promote the inclu-
sion of pregnant and lactating women in clinical re-
search, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Advancing Safe Medi-
4
cations for Moms and Babies Act of 2022’’. 
5
SEC. 2. UPDATING FDA REGULATIONS TO REMOVE PREG-
6
NANT WOMEN AS A VULNERABLE RESEARCH 
7
8
(a) PURPOSES.—The purposes of this section are— 
9
04:18 Dec 21, 2022
H9487
2 
•HR 9487 IH
(1) to facilitate compliance with applicable Fed-
1
eral regulations relating to the protection of preg-
2
nant women participating in research as subjects; 
3
and 
4
(2) to promote the inclusion of pregnant women 
5
in clinical research. 
6
(b) HARMONIZATION.—For the purposes specified in 
7
subsection (a), the Secretary of Health and Human Serv-
8
ices (in this Act referred to as the ‘‘Secretary’’) shall, to 
9
the extent practicable and consistent with other applicable 
10
statutes, issue such regulations as may be appropriate to 
11
harmonize the regulations of the Food and Drug Adminis-
12
tration relating to the protection of human subjects, in-
13
cluding parts 50 and 56 of title 21, Code of Federal Regu-
14
lations, with the latest regulations of the Department of 
15
Health and Human Services relating to the inclusion of 
16
pregnant women as subjects in clinical research. 
17
(c) DEADLINE.—The Secretary of Health and 
18
Human Services shall finalize the regulations required by 
19
subsection (b) not later than 180 days after the date of 
20
enactment of this Act. 
21
SEC. 3. CLEARINGHOUSE OF CLINICAL TRIALS AND REG-
22
ISTRIES. 
23
(a) IN GENERAL.—The Secretary, acting through the 
24
Director of the National Institutes of Health, and in con-
25
04:18 Dec 21, 2022
H9487
3 
•HR 9487 IH
sultation with the Commissioner of Food and Drugs and 
1
the heads of other relevant Federal departments and agen-
2
cies, shall establish and maintain a national clearinghouse 
3
of educational materials and current information on reg-
4
istries and clinical trials that enroll pregnant and lactating 
5
women in order to— 
6
(1) enable pregnant and lactating women, their 
7
families, and health care professionals to easily iden-
8
tify and enroll in registries and clinical trials; 
9
(2) educate pregnant and lactating women, 
10
their families, and health care professionals on the 
11
importance of enrolling in registries and clinical 
12
trials; and 
13
(3) inform pregnant and lactating women, their 
14
families, and health care professionals about the 
15
general requirements, commitments, and benefits as-
16
sociated with participating in a registry or clinical 
17
trial. 
18
(b) REQUIREMENTS.—The Secretary, acting through 
19
the Director of the National Institutes of Health, and in 
20
consultation with the Commissioner of Food and Drugs 
21
and the heads of other relevant Federal departments and 
22
agencies, shall ensure that the clearinghouse under sub-
23
section (a)— 
24
(1) is accessible by means of the internet; 
25
04:18 Dec 21, 2022
H9487
4 
•HR 9487 IH
(2) is updated on a regular basis, not less than 
1
quarterly; 
2
(3) is designed for consumers, incorporates a 
3
user-friendly interface, and is searchable; 
4
(4) includes links to related public and private 
5
sector resources on registries and clinical trials de-
6
scribed in subsection (a); and 
7
(5) is available to the public by October 1, 
8
2025. 
9
(c) PLANNING.— 
10
(1) IN GENERAL.—In establishing the clearing-
11
house under subsection (a), the Secretary, shall— 
12
(A) develop criteria for which registries 
13
and clinical trials are eligible for listing in the 
14
clearinghouse under subsection (a); 
15
(B) establish a procedure for archiving 
16
closed registries and clinical trials; and 
17
(C) identify educational resources needed 
18
for the clearinghouse. 
19
(2) PUBLIC INPUT.—The Secretary shall solicit 
20
public input on content to be included in the clear-
21
inghouse under subsection (a). 
22
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
23
out this section, there are authorized to be appropriated— 
24
04:18 Dec 21, 2022
H9487
5 
•HR 9487 IH
(1) $4,000,000 for the period of fiscal years 
1
2023 through 2024; and 
2
(2) $3,000,000 for the period of fiscal years 
3
2025 through 2027. 
4
SEC. 4. COORDINATING COMMITTEE ON RESEARCH SPE-
5
CIFIC 
TO 
PREGNANT 
AND 
LACTATING 
6
WOMEN. 
7
(a) ESTABLISHMENT.—Not later than 90 days after 
8
the date of enactment of this Act, the Secretary shall es-
9
tablish a committee, in accordance with the Federal Advi-
10
sory Committee Act (5 U.S.C. App.), to be known as the 
11
Committee on Research Specific to Pregnant and Lac-
12
tating Women or the PRGLAC Committee (in this section 
13
referred to as the ‘‘Committee’’) to advise on coordinating 
14
Federal activities to address gaps in knowledge and re-
15
search regarding safe and effective therapies for pregnant 
16
and lactating women. 
17
(b) DUTIES.—The Committee shall— 
18
(1) advise on coordinating Federal activities to 
19
promote the inclusion of pregnant and lactating 
20
women in clinical research; 
21
(2) promote opportunities for Federal agencies 
22
and private actors to advance the inclusion of preg-
23
nant and lactating women in clinical research; 
24
04:18 Dec 21, 2022
H9487
6 
•HR 9487 IH
(3) develop and annually update a summary of 
1
Federal agency progress toward implementing rec-
2
ommendations included in the September 2018 Re-
3
port to the Secretary of Health and Human Serv-
4
ices, and the August 2020 Report Implementation 
5
Plan to the Secretary of Health and Human Serv-
6
ices, prepared by the Task Force on Research Spe-
7
cific to Pregnant Women and Lactating Women; 
8
(4) identify new recommendations for the Sec-
9
retary regarding Federal activities to address gaps 
10
in knowledge and research regarding safe and effec-
11
tive therapies for pregnant and lactating women; 
12
and 
13
(5) receive updates on private sector and inter-
14
national efforts to include pregnant and lactating 
15
women in clinical research. 
16
(c) MEMBERSHIP.— 
17
(1) IN
GENERAL.—The Committee shall be 
18
composed of— 
19
(A) the Federal members listed in para-
20
graph (2); and 
21
(B) the non-Federal members appointed 
22
pursuant to paragraph (3). 
23
04:18 Dec 21, 2022
H9487
7 
•HR 9487 IH
(2) FEDERAL MEMBERS.—The Federal mem-
1
bers of the Committee shall consist of the following 
2
Federal officials (or their designees): 
3
(A) The Director of the Centers for Dis-
4
ease Control and Prevention. 
5
(B) The Director of the National Institutes 
6
of Health, the Director of the Eunice Kennedy 
7
Shriver National Institute of Child Health and 
8
Human Development, the Director of the Office 
9
of Research on Women’s Health of the National 
10
Institutes of Health, and the directors of such 
11
other national research institutes and national 
12
centers of the National Institutes of Health as 
13
the Secretary determines appropriate. 
14
(C) The Commissioner of Food and Drugs. 
15
(D) The Director of the Agency for 
16
Healthcare Research and Quality. 
17
(E) The Director of the Office on Women’s 
18
Health of the Department of Health and 
19
Human Services. 
20
(F) The Director of the National Vaccine 
21
Program. 
22
(G) The Director of the Office for Human 
23
Research Protections of the Department of 
24
Health and Human Services. 
25
04:18 Dec 21, 2022
H9487
8 
•HR 9487 IH
(H) The Administrator of Health Re-
1
sources and Services Administration. 
2
(I) The head of any other research-related 
3
agency or department not described in subpara-
4
graphs (A) through (H) as the Secretary deter-
5
mines appropriate, which may include the De-
6
partment of Veterans Affairs and the Depart-
7
ment of Defense. 
8
(3) NON-FEDERAL MEMBERS.— 
9
(A) IN GENERAL.—The non-Federal mem-
10
bers of the Committee shall consist of— 
11
(i) representatives from relevant med-
12
ical societies with subject matter expertise 
13
on pregnant women, lactating women, or 
14
children; 
15
(ii) representatives from nonprofit or-
16
ganizations with expertise related to the 
17
health of women and children; 
18
(iii) relevant industry representatives; 
19
(iv) individuals with ethical and legal 
20
expertise in clinical trials and research; 
21
(v) representatives from relevant non-
22
profit organizations with expertise in clin-
23
ical research; and 
24
04:18 Dec 21, 2022
H9487
9 
•HR 9487 IH
(vi) other representatives, as the Sec-
1
retary determines appropriate. 
2
(B) LIMITATIONS.—The non-Federal mem-
3
bers of the Committee shall compose not more 
4
than one-half, and not less than one-third, of 
5
the total membership of the Committee. 
6
(C) APPOINTMENT.—The Secretary shall 
7
appoint the non-Federal members of the Com-
8
mittee. 
9
(D) TERMS.—The non-Federal members of 
10
the Committee shall serve for a term of 4 years, 
11
and may be reappointed for 1 additional 4-year 
12
term. Any non-Federal member appointed to fill 
13
a vacancy for an unexpired term shall be ap-
14
pointed for the remainder of such term. A non- 
15
Federal member may serve after the expiration 
16
of the member’s term until a successor has 
17
taken office. 
18
(d) ADMINISTRATIVE SUPPORT.—The Secretary shall 
19
provide the Committee such administrative support as the 
20
Secretary determines to be necessary for carrying out this 
21
section. 
22
(e) MEETINGS.—The Committee shall meet at least 
23
2 times each year and shall convene public meetings, as 
24
appropriate, to fulfill its duties under subsection (b). 
25
04:18 Dec 21, 2022
H9487
10 
•HR 9487 IH
(f) REPORT TO CONGRESS.— 
1
(1) IN GENERAL.—Not later than 1 year after 
2
the date of enactment of this Act, and every other 
3
year thereafter, the Committee shall prepare and 
4
submit to the Secretary, the Committee on Health, 
5
Education, Labor, and Pensions of the Senate, and 
6
the Committee on Energy and Commerce of the 
7
House of Representatives a report on— 
8
(A) the progress of Federal agencies in im-
9
plementing the recommendations and imple-
10
mentation plan described in subsection (b)(3); 
11
(B) Federal activities undertaken to ad-
12
vance the inclusion of pregnant and lactating 
13
women in clinical research; and 
14
(C) additional recommendations for the 
15
Secretary regarding Federal activities to ad-
16
dress gaps in knowledge and research regarding 
17
safe and effective therapies for pregnant and 
18
lactating women. 
19
(2) 
PUBLIC
AVAILABILITY.—The 
Secretary 
20
shall make the reports required by paragraph (1) 
21
available on a public website of the Department of 
22
Health and Human Services. 
23
(g) SUPPLEMENTAL
REPORT
ON
DEPARTMENT 
24
GUIDANCE.— 
25
04:18 Dec 21, 2022
H9487
11 
•HR 9487 IH
(1) IN GENERAL.—Not later than 2 years after 
1
the date of enactment of this Act, the Committee 
2
shall prepare and submit to the Secretary, the Com-
3
mittee on Health, Education, Labor, and Pensions 
4
of the Senate, and the Committee on Energy and 
5
Commerce of the House of Representatives a report 
6
to inform guidance of the Department of Health and 
7
Human Services to facilitate the conduct of clinical 
8
research involving pregnant and lactating women. 
9
(2) CONTENTS.—The report under paragraph 
10
(1) shall include— 
11
(A) information on which clinical studies 
12
require consent from both biological parents, in-
13
cluding information quantifying how requiring 
14
consent from both biological parents limits par-
15
ticipation in such clinical studies; 
16
(B) best practices and recommendations 
17
for institutional review boards related to the in-
18
clusion of pregnant and lactating women in 
19
clinical research, including information on suc-
20
cesses and challenges of using a centralized in-
21
stitutional review board; and 
22
(C) an evaluation of statutory programs 
23
enacted to spur pediatric-specific information in 
24
Food and Drug Administration-approved thera-
25
04:18 Dec 21, 2022
H9487
12 
•HR 9487 IH
pies, such as the Best Pharmaceuticals for Chil-
1
dren Act (Public Law 107–109) and the Pedi-
2
atric Research Equity Act of 2008 (Public Law 
3
108–155), and how approaches taken in such 
4
programs can be applied to clinical research in-
5
cluding pregnant and lactating women. 
6
(3) 
PUBLIC
AVAILABILITY.—The 
Secretary 
7
shall make the report required by paragraph (1) 
8
available on a public website of the Department of 
9
Health and Human Services. 
10
(h) TERMINATION.— 
11
(1) IN GENERAL.—The Committee shall termi-
12
nate on the date that is 5 years after the date on 
13
which the Committee is established under subsection 
14
(a). 
15
(2) EXTENSION.—The Secretary may extend 
16
the operation of the Committee for up to 3 addi-
17
tional 2-year periods following the 5-year period de-
18
scribed in paragraph (1) if the Secretary determines 
19
that the extension is appropriate to monitor the im-
20
plementation of the recommendations and implemen-
21
tation plan described in subsection (b)(3) or any ad-
22
ditional recommendations made by the Committee. 
23
04:18 Dec 21, 2022
H9487
13 
•HR 9487 IH
SEC. 5. RAISING AWARENESS OF RESEARCH THAT IN-
1
CLUDES PREGNANT AND LACTATING WOMEN 
2
IN CLINICAL RESEARCH. 
3
(a) IN GENERAL.—The Secretary, acting through the 
4
Director of the National Institutes of Health, in consulta-
5
tion with the heads of other relevant Federal agencies, 
6
shall establish and implement an education campaign de-
7
signed to— 
8
(1) educate the public on the importance of— 
9
(A) including pregnant and lactating 
10
women in clinical research to better inform 
11
health care decisions on the safety and effec-
12
tiveness of medications for pregnant and lac-
13
tating women before, during, and after preg-
14
nancy; 
15
(B) registries and clinical trials that in-
16
clude pregnant and lactating women; 
17
(2) encourage and facilitate participation by 
18
pregnant and lactating women in clinical research; 
19
(3) improve the general understanding of the 
20
critical role registries and other postmarket surveil-
21
lance activities have in collecting data related to the 
22
use of medications by pregnant and lactating 
23
women; 
24
04:18 Dec 21, 2022
H9487
14 
•HR 9487 IH
(4) improve the understanding of available clin-
1
ical trials and registries that enroll pregnant and 
2
lactating women; 
3
(5) encourage pregnant and lactating women to 
4
seek additional information about such opportunities 
5
to participate in clinical research; 
6
(6) encourage health care providers to make in-
7
formation on clinical research available to pregnant 
8
and lactating women; and 
9
(7) facilitate access to and enrollment in such 
10
research by pregnant and lactating women. 
11
(b) CONSULTATION.—In carrying out this section, 
12
the Secretary shall consult with— 
13
(1) nonprofit organizations with expertise re-
14
lated to the health of women and children, including 
15
those representing populations with high rates of 
16
maternal mortality and morbidity; 
17
(2) representatives from relevant medical soci-
18
eties with subject matter expertise on pregnant 
19
women, lactating women, or children; 
20
(3) relevant industry representatives; and 
21
(4) other representatives, as appropriate. 
22
(c) PLANNING.—In establishing the campaign under 
23
subsection (a), the Secretary, acting through the Director 
24
04:18 Dec 21, 2022
H9487
15 
•HR 9487 IH
of the National Institutes of Health, in consultation with 
1
the heads of other relevant Federal agencies, shall— 
2
(1) conduct a needs assessment to— 
3
(A) evaluate existing resources; and 
4
(B) identify barriers to awareness and op-
5
portunities to fill gaps and address barriers; 
6
(2) identify target audiences for the campaign; 
7
(3) identify best practices to reach each such 
8
target audience; 
9
(4) test appropriate messaging strategies, in-
10
cluding risk communication messaging, for each tar-
11
get audience; and 
12
(5) coordinate with the clearinghouse estab-
13
lished under section 3. 
14
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
15
out this section, there is authorized to be appropriated 
16
$5,000,000 for the period of fiscal years 2023 through 
17
2027. 
18
SEC. 6. RESEARCH PRIORITIZATION PROCESS FOR PREG-
19
NANT AND LACTATING WOMEN AT THE EU-
20
NICE KENNEDY SHRIVER NATIONAL INSTI-
21
TUTE OF CHILD HEALTH AND HUMAN DEVEL-
22
OPMENT. 
23
(a) IN GENERAL.—The Director of the National In-
24
stitutes of Health, acting through the Director of the Eu-
25
04:18 Dec 21, 2022
H9487
16 
•HR 9487 IH
nice Kennedy Shriver National Institute of Child Health 
1
and Human Development (referred to in this section as 
2
‘‘NICHD’’), shall carry out priority research projects on 
3
existing and new medications prescribed for pregnant and 
4
lactating women. 
5
(b) RESEARCH PRIORITIZATION PROCESS.—The Di-
6
rector of the National Institutes of Health shall establish 
7
a research prioritization process to determine which pro-
8
posed research projects should receive priority funding 
9
under this section. Such research prioritization process 
10
shall take into account the following factors: 
11
(1) The available evidence, including whether 
12
there is an unmet medical need or gap in scientific 
13
information relevant to treatment of pregnant and 
14
lactating women with specific diseases or conditions. 
15
(2) The feasibility of research, including the 
16
prevalence of a disease or condition in pregnant and 
17
lactating women and the availability of investigators 
18
with expertise in studying such disease or condition. 
19
(3) The potential impact of research, including 
20
the severity of the disease or condition in pregnant 
21
and lactating women, the current cost of treating 
22
the disease or condition in pregnant and lactating 
23
women, the frequency of use of the drug in pregnant 
24
and lactating women, and the availability of alter-
25
04:18 Dec 21, 2022
H9487
17 
•HR 9487 IH
native treatments for the disease or condition in 
1
pregnant and lactating women. 
2
(c) CONSULTATION.—In developing the research 
3
prioritization process described in subsection (b), the Di-
4
rector of the National Institutes of Health shall seek feed-
5
back from— 
6
(1) the existing research networks of the Na-
7
tional Institute of Child Health and Human Devel-
8
opment with expertise in clinical research involving 
9
pregnant and lactating women; 
10
(2) relevant medical societies with subject mat-
11
ter expertise on pregnant women, lactating women, 
12
or children; and 
13
(3) nonprofit organizations with expertise re-
14
lated to the health of pregnant women, lactating 
15
women, or children, including those representing 
16
populations with high rates of maternal mortality 
17
and morbidity. 
18
(d) PUBLIC COMMENT.—The Secretary shall provide 
19
an opportunity for public comment on the program under 
20
this section. 
21
(e) ACCOUNTABILITY AND OVERSIGHT.— 
22
(1) WORK
PLAN.—Not later than 180 days 
23
after the date of enactment of this Act, the Director 
24
of the National Institutes of Health shall submit to 
25
04:18 Dec 21, 2022
H9487
18 
•HR 9487 IH
the Committee on Health, Education, Labor, and 
1
Pensions and the Committee on Appropriations of 
2
the Senate and the Committee on Energy and Com-
3
merce and the Committee on Appropriations of the 
4
House of Representatives a work plan for— 
5
(A) funding priority research projects 
6
under subsection (a); and 
7
(B) developing the research prioritization 
8
process under subsection (b). 
9
(2) REPORTS.—Not later than October 1 of 
10
each of fiscal years 2023 through 2027, the Director 
11
of the National Institutes of Health shall submit to 
12
the Committee on Health, Education, Labor, and 
13
Pensions and the Committee on Appropriations of 
14
the Senate and the Committee on Energy and Com-
15
merce and the Committee on Appropriations of the 
16
House of Representatives a report on the program 
17
under this section, including— 
18
(A) the amount of money obligated or ex-
19
pended in the prior fiscal year for each priority 
20
research project under subsection (a); 
21
(B) a description of each such project; and 
22
(C) the rationale for prioritizing each such 
23
project according to the process under sub-
24
section (b). 
25
04:18 Dec 21, 2022
H9487
19 
•HR 9487 IH
(f) AUTHORIZATION OF APPROPRIATIONS.—To carry 
1
out this section, there is authorized to be appropriated 
2
$50,000,000 for the period of fiscals year 2023 through 
3
2027. 
4
Æ 
04:18 Dec 21, 2022
H9487
